
In a randomized trial (428 patients), 46.4% achieved sustained remission at 52 weeks versus 29.0% with placebo (P=0.002). The 7.5 mg dose showed no superiority. Key secondary outcomes, including time to flare and glucocorticoid exposure, also favored upadacitinib 15 mg. No major cardiovascular events occurred. These findings support upadacitinib 15 mg as a promising treatment option.
Like
Save
Share